|

Zeprumetostat Clinical Trials

3 actively recruiting trials

▲ +1 trial since July 2026

Also known as: SHR2554

Pipeline

Phase 2: 2Phase 1/2: 1

Top Sponsors

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
  • Rong Tao1
  • Institute of Hematology & Blood Diseases Hospital, China1

Indications

  • Cancer3
  • Relapsed or Refractory NK/T-Cell Lymphoma1
  • NK/T-cell Lymphoma1
  • Bladder Urothelial Carcinoma1
  • Extranodal NK/T-cell Lymphoma1

Other3 trials

Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma
Phase 2
Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer
Phase 2
Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.